The Administration Core acts to ensure that the research and programmatic goals of the Healthy Aging and Senile Dementia program project grant (HASD PPG) are met. The administrative leadership consists of the Director (Morris) and the Executive Director (Moulder). They are assisted by the Executive Committee that includes these individuals, leaders of Cores and Projects, and other senior faculty. The Administration Core supports, monitors, and coordinates the activities of all components of the HASD PPG. It will annually convene an External Advisory Committee to review activities and progress.
The specific aims are to: 1) Coordinate and integrate all Cores and Projects and monitor the effectiveness of the PPG toward achieving the stated goals. 2) Provide administrative and budgetary support and oversight to the Cores and Projects, ensuring appropriate utilization of the funds in all PPG activities. 3) Arrange for periodic external review and advice regarding PPG goals and programs. 4) Provide oversight and administrative support for data integration with Core C: Biostatistics to maintain and monitor an integrated database for the PPG 5) Coordinate the collaborations between Core E: Imaging and Avid/Lilly regarding amyloid imaging with [18F]florbetapir 6) Facilitate inclusion of HASD participants and data in other national AD initiatives, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Alzheimer's Disease Genetics Consortium (ADGC), trials orchestrated by the Alzheimer's Disease Cooperative Study (ADCS), and as acceptable, the National Alzheimer Coordinating Center (NACC).
Core A: Administration Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.
|Lucey, Brendan P; Mawuenyega, Kwasi G; Patterson, Bruce W et al. (2016) Associations Between Î²-Amyloid Kinetics and the Î²-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol :|
|Esparza, Thomas J; Wildburger, Norelle C; Jiang, Hao et al. (2016) Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Sci Rep 6:38187|
|McKee, Ann C; Cairns, Nigel J; Dickson, Dennis W et al. (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 131:75-86|
|Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61|
|Jin, Sheng Chih; Benitez, Bruno A; Deming, Yuetiva et al. (2016) Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. Methods Mol Biol 1303:299-314|
|Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43|
|Van Schependom, Jeroen; Jain, Saurabh; Cambron, Melissa et al. (2016) Reliability of measuring regional callosal atrophy in neurodegenerative diseases. Neuroimage Clin 12:825-831|
|Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50|
|Su, Yi; Rubin, Brian B; McConathy, Jonathan et al. (2016) Impact of MR-Based Attenuation Correction on Neurologic PET Studies. J Nucl Med 57:913-7|
|Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9|
Showing the most recent 10 out of 756 publications